Cargando…

Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?

Background and Objectives: This investigation aimed to determine the impacts of concurrent proton pump inhibitors (PPIs) on progression-free survival (PFS) in patients with hormone receptor-positive and HER2-negative metastatic breast cancer managed with palbociclib or ribociclib as either the initi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Odabas, Hatice, Dogan, Akif, Ozcelik, Melike, Yildirim, Sedat, Ozkerim, Ugur, Turan, Nedim, Yildirim, Mahmut Emre, Gumus, Mahmut
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052377/ https://www.ncbi.nlm.nih.gov/pubmed/36984558 http://dx.doi.org/10.3390/medicina59030557

Ejemplares similares

Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer?
por: Ayhan, Murat, et al.
Publicado: (2021)

Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study
por: Eser, Kadir, et al.
Publicado: (2022)

The Prognostic Utility of the Metastatic Lymph Node Ratio and the Number of Regional Lymph Nodes Removed from Patients with Small Bowel Adenocarcinomas
por: Aydin, Dincer, et al.
Publicado: (2023)

Ribociclib and palbociclib-induced erythema multiforme: a case report
por: Vrana, Eleni, et al.
Publicado: (2022)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
por: Zhu, Zhimin, et al.
Publicado: (2023)

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
por: Bellet, Meritxell, et al.
Publicado: (2019)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom
por: Suri, Gaurav, et al.
Publicado: (2019)

Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
por: Jin, Dan, et al.
Publicado: (2019)

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer
por: Tremblay, Gabriel, et al.
Publicado: (2018)

Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
por: Iuliani, Michele, et al.
Publicado: (2022)

Supracondylar extra-articular femur fracture after cementless unicompartmental knee replacement: A rare complication
por: Karagüven, Doğaç, et al.
Publicado: (2021)

Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer
por: Lee, Ju-Eun, et al.
Publicado: (2023)

Characteristics and clinical outcome of pT1a-b node-negative breast cancer
por: Oyman, Abdilkerim, et al.
Publicado: (2021)

Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application
por: Posocco, Bianca, et al.
Publicado: (2020)

Rapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach
por: Mlinarić, Zvonimir, et al.
Publicado: (2022)

Treatment Approaches in 102 Elderly Patients With Non-Small Cell Lung Cancer
por: Cihan, Sener, et al.
Publicado: (2015)

Comparison of Biparametric and Multiparametric Prostate Magnetic Resonance Imaging in Predicting Oncologic Outcomes After Radical Prostatectomy
por: EFILOGLU, Ozgur, et al.
Publicado: (2022)

Trends in the treatment of urinary stone disease in Turkey
por: Yildirim, Kadir, et al.
Publicado: (2018)

Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib
por: Del Re, Marzia, et al.
Publicado: (2022)

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2− advanced or metastatic breast cancer in Spain
por: Galve-Calvo, Elena, et al.
Publicado: (2018)

Cost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation
por: Al-Ziftawi, Nour Hisham, et al.
Publicado: (2022)

Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer
por: Ercelep, Özlem, et al.
Publicado: (2020)

Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
por: Cejuela, Mónica, et al.
Publicado: (2023)

Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice
por: Rath, Sushmita, et al.
Publicado: (2021)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

A novel urethra compression technique using Turkish continence device for male urinary incontinence
por: ODABAŞ, Öner, et al.
Publicado: (2020)

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer
por: Fasching, Peter A, et al.
Publicado: (2021)

Systematic assessment of complications after laparoscopic colorectal surgery for advanced colorectal cancer: A retrospective study using Clavien-Dindo classification, 5-year experience
por: Degerli, Mahmut Said, et al.
Publicado: (2022)

Disparate impact pandemic framing decreases public concern for health consequences
por: Yildirim, Ugur
Publicado: (2020)

Long-term effects of antihypertensive medications on bone mineral density in men older than 55 years
por: Ağaçayak, Kamil Serkan, et al.
Publicado: (2014)

Psychological impacts of COVID-19 pandemic in cancer patients on active treatment
por: Koca, Sinan, et al.
Publicado: (2022)

NAT2 Gene Polymorphisms in Turkish Patients with Psoriasis Vulgaris
por: Dursun, Recep, et al.
Publicado: (2018)

Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model
por: Darvishi, Ali, et al.
Publicado: (2023)

Escitalopram co-prescription in anastrozole-treated breast cancer patients
por: Ozyurt, Hazan, et al.
Publicado: (2022)

Surface enhanced Raman spectroscopy as a novel tool for rapid quantification of heroin and metabolites in saliva
por: AKÇAN, Ramazan, et al.
Publicado: (2020)

Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
por: Del Re, M., et al.
Publicado: (2021)

Exploring the Relationships between Structure and Antimicrobial Potency of Quinolinequinones
por: Mataracı-Kara, Emel, et al.
Publicado: (2022)

Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry
por: Martínez-Chávez, Alejandra, et al.
Publicado: (2019)

Infrapatellar Fat Pad-Derived Stem Cell-Based Regenerative Strategies in Orthopedic Surgery
por: Huri, Pinar Yilgor, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fteftbiq3v3l9r5rcbc0jcknhb